NCT03126916 2026-02-27
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Phase 3 Recruiting
Children's Oncology Group
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Emory University
New Approaches to Neuroblastoma Therapy Consortium
Princess Maxima Center for Pediatric Oncology
Nationwide Children's Hospital
N.N. Petrov National Medical Research Center of Oncology